Annexin A5

1 clinical trial

1 abstract

1 indication

Indication

Retinal Vein Occlusion

Abstract

Novel protein drug conjugate ANXV-chemo and cytotoxic and anti-proliferative effects against human triple-negative breast cancer in vitro.

Org: Annexin Pharmaceuticals AB (publ), Truly Labs AB, ALMIR Conseil,

Clinical trial

Near-Infrared Fluorescence Molecular Imaging of ANXV-800CW to Visualize Its Biodistribution in the Eyes of Patients Suffering From Retinal Vein Occlusion

Status: Recruiting, Estimated PCD: 2024-01-01